Literature DB >> 25250111

Simultaneous gastric adenocarcinoma and gastrointestinal stromal tumor of the stomach: a case report.

Jalaluddin Khoshnevis1, Azadeh Rakhshan2, Mohammad Reza Sobhiyeh1, Barmak Gholizadeh1, Ali Rahbari2, Farideh Adhami1, Saran Lotfollahzadeh2.   

Abstract

Simultaneous a collision tumor of stomach consisting of adenocarcinoma and Gastrointestinal Stromal Tumor (GIST) is very rare based on our knowledge. This coexistence has rarely been reported in literatures. We report a case of 64-year-old woman who has diagnosed with prepyloric poorly-differentiated diffuse signet-ring cell type adenocarcinoma and has undergone an elective D2 total gastrectomy. During operation another mass in fundic body region has found. The pathologic examination of the mass has shown GIST. Immunohistochemical staining for CD117 and Desmin was positive whilst that for S100 was negative. This case reports the simultaneous two tumors development of different histotypes and natures in the same organ.

Entities:  

Keywords:  Adenocarcinoma; Gastrointestinal stromal tumor; Stomach cancer

Year:  2013        PMID: 25250111      PMCID: PMC4142907     

Source DB:  PubMed          Journal:  Iran J Cancer Prev        ISSN: 2008-2398


  26 in total

1.  Synchronous Adenocarcinoma and Gastrointestinal Stromal Tumor of the Stomach Treated by a Combination of Laparoscopy-assisted Distal Gastrectomy and Wedge Resection.

Authors:  Sang-Ho Jeong; Young-Joon Lee; Soon-Tae Park; Sang-Kyung Choi; Soon-Chan Hong; Eun-Jung Jung; Young-Tae Ju; Chi-Young Jeong; Woo-Song Ha
Journal:  J Gastric Cancer       Date:  2011-03-31       Impact factor: 3.720

2.  Tumor production in the glandular stomach and alimentary tract of the rat by N-methyl-N'-nitro-N-nitrosoguanidine.

Authors:  T Sugimura; S Fujimura; T Baba
Journal:  Cancer Res       Date:  1970-02       Impact factor: 12.701

3.  Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors.

Authors:  Eduardo A Perez; Alan S Livingstone; Dido Franceschi; Caio Rocha-Lima; David J Lee; Nicole Hodgson; Merce Jorda; Leonidas G Koniaris
Journal:  J Am Coll Surg       Date:  2006-04       Impact factor: 6.113

Review 4.  Gastrointestinal stromal tumors: clinical profile, pathogenesis, treatment strategies and prognosis.

Authors:  Arash Nowain; Hetal Bhakta; Shireen Pais; Gary Kanel; Sumita Verma
Journal:  J Gastroenterol Hepatol       Date:  2005-06       Impact factor: 4.029

5.  Synchronous primary adenocarcinoma and gastrointestinal stromal tumor in the stomach: a report of two cases.

Authors:  Sema Bircan; Ozden Candir; Serife Aydin; Sirin Başpinar; Mahmut Bülbül; Nilgün Kapucuoğlu; Nermin Karahan; Metin Ciriş
Journal:  Turk J Gastroenterol       Date:  2004-09       Impact factor: 1.852

6.  Experimental models for gastric leiomyosarcoma. The effects of N-methyl-N'-nitro-N-nitrosoguanidine in combination with stress, aspirin, or sodium taurocholate.

Authors:  A Cohen; S A Geller; I Horowitz; L S Toth; J L Werther
Journal:  Cancer       Date:  1984-03-01       Impact factor: 6.860

Review 7.  Diagnosis of gastrointestinal stromal tumors: A consensus approach.

Authors:  Christopher D M Fletcher; Jules J Berman; Christopher Corless; Fred Gorstein; Jerzy Lasota; B Jack Longley; Markku Miettinen; Timothy J O'Leary; Helen Remotti; Brian P Rubin; Barry Shmookler; Leslie H Sobin; Sharon W Weiss
Journal:  Hum Pathol       Date:  2002-05       Impact factor: 3.466

8.  Gastric stromal tumors. Reappraisal of histogenesis.

Authors:  M T Mazur; H B Clark
Journal:  Am J Surg Pathol       Date:  1983-09       Impact factor: 6.394

9.  Synchronous gastric gastrointestinal stromal tumor and signet-ring cell adenocarcinoma: a case report.

Authors:  Fang-Yi Lee; Yee-Jee Jan; John Wang; Cheng-Chan Yu; Cheng-Chung Wu
Journal:  Int J Surg Pathol       Date:  2007-10       Impact factor: 1.271

10.  Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study.

Authors:  J Verweij; A van Oosterom; J-Y Blay; I Judson; S Rodenhuis; W van der Graaf; J Radford; A Le Cesne; P C W Hogendoorn; E D di Paola; M Brown; O S Nielsen
Journal:  Eur J Cancer       Date:  2003-09       Impact factor: 9.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.